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Pathomimetic avatars reveal divergent roles
of microenvironment in invasive transition
of ductal carcinoma in situ
Mansoureh Sameni1, Dora Cavallo-Medved1,2*, Omar E. Franco3,4, Anita Chalasani1, Kyungmin Ji1, Neha Aggarwal5,
Arulselvi Anbalagan1, Xuequn Chen5, Raymond R. Mattingly1,6, Simon W. Hayward3,4,7 and Bonnie F. Sloane1,2,6
Abstract
Background: The breast tumor microenvironment regulates progression of ductal carcinoma in situ (DCIS) to invasive
ductal carcinoma (IDC). However, it is unclear how interactions between breast epithelial and stromal cells can drive
this progression and whether there are reliable microenvironmental biomarkers to predict transition of DCIS to IDC.
Methods: We used xenograft mouse models and a 3D pathomimetic model termed mammary architecture and
microenvironment engineering (MAME) to study the interplay between human breast myoepithelial cells (MEPs) and
cancer-associated fibroblasts (CAFs) on DCIS progression.
Results: Our results show that MEPs suppress tumor formation by DCIS cells in vivo even in the presence of CAFs. In
the in vitro MAME model, MEPs reduce the size of 3D DCIS structures and their degradation of extracellular matrix. We
further show that the tumor-suppressive effects of MEPs on DCIS are linked to inhibition of urokinase plasminogen
activator (uPA)/urokinase plasminogen activator receptor (uPAR)-mediated proteolysis by plasminogen activator
inhibitor 1 (PAI-1) and that they can lessen the tumor-promoting effects of CAFs by attenuating interleukin 6 (IL-6)
signaling pathways.
Conclusions: Our studies using MAME are, to our knowledge, the first to demonstrate a divergent interplay between
MEPs and CAFs within the DCIS tumor microenvironment. We show that the tumor-suppressive actions of MEPs are
mediated by PAI-1, uPA and its receptor, uPAR, and are sustained even in the presence of the CAFs, which themselves
enhance DCIS tumorigenesis via IL-6 signaling. Identifying tumor microenvironmental regulators of DCIS progression
will be critical for defining a robust and predictive molecular signature for clinical use.
Keywords: Ductal carcinoma in situ, Myoepithelial cells, Fibroblasts, Tumor microenvironment, Proteolysis, 3D
pathomimetic model, Heterotypic xenografts, Urokinase plasminogen activator, Interleukin 6
Background
The breast cancer microenvironment is composed of epi-
thelial tumor cells admixed with myoepithelial cells
(MEPs); stromal cells, including fibroblasts as well as vas-
cular and immune cells; and extracellular matrix (ECM)
molecules [1–3]. Cross talk among breast epithelial and
stromal cells, along with changes in both their gene expres-
sion and enzymatic activities, has been shown to be a driver
of disease progression [4–6]. Hence, efforts are focused on
targeting tumor-promoting factors of the breast micro-
environment as an alternative therapeutic approach against
metastatic and treatment-resistant breast cancers [7–9].
In normal breast tissue, MEPs support and promote
differentiation and polarity of epithelial acinar structures
and aid in expelling milk from acini into adjoining epithe-
lial ducts [2, 10]. MEPs produce the basement membrane
that separates the luminal epithelial cells from the sur-
rounding ECM and exhibit a tumor-suppressive pheno-
type by inhibiting cell growth, invasion, and angiogenesis
[10, 11]. Loss of the protective role of MEPs in the breast
tumor microenvironment is correlated with the transition
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of ductal carcinoma in situ (DCIS) to invasive ductal
carcinoma (IDC), a key event in the progression of breast
cancer [12].
Cancer-associated fibroblasts (CAFs) have been shown
to play a significant role in promoting breast cancer
progression and metastasis through paracrine signaling
[13–15]. CAFs secrete high levels of growth factors, che-
mokines, cytokines, and proteases that enhance tumor
cell proliferation, angiogenesis, and invasion [16, 17]. In
both in vivo and in vitro studies of DCIS, CAFs have
been shown to induce an invasive DCIS phenotype in
parallel with an increase in matrix metalloprotease
(MMP)-14 expression and MMP-9 activity [18, 19]. We
have observed that DCIS cell proliferation, ECM prote-
olysis, migration, and invasion are increased in the
presence of normal fibroblasts induced to secrete hep-
atocyte growth factor (HGF) [20] and CAFs secreting
interleukin 6 (IL-6) [21]. Others have also demonstrated
a tumor-promoting role in breast and ovarian cancers
for IL-6 secreted from CAFs [22, 23]. Both direct and
indirect correlations between expression of IL-6 and up-
regulation of proteases involved in ECM degradation
(e.g., cathepsin B, MMPs, and urokinase plasminogen acti-
vator [uPA]) and invasion have been reported [21, 24–27].
We have recently shown that paracrine IL-6 signaling be-
tween DCIS cells and CAFs facilitates tumor cell growth
and migration in part through cathepsin B-mediated ECM
degradation [21].
One of the challenges in treating patients with DCIS is
the lack of reliable biomarkers that can predict transition
of DCIS to IDC. In vivo mouse models, such as subcuta-
neous and orthotopic approaches including intraductal
injection, have provided valuable tools to study DCIS
progression [19, 28, 29]. It is often difficult, however, to
delineate the complex molecular mechanisms that drive
the invasive transition of DCIS using only in vivo models.
In this respect, the advantage of heterotypic 3D in vitro
models is that they can be designed to examine the cross
talk between epithelial and stromal cells within the con-
text of a defined microenvironment [30, 31]. Moreover,
3D in vitro models can be used to elucidate the role of
noncellular microenvironmental factors (e.g., ECM mole-
cules, pH, oxygen, biomechanical forces) on disease pro-
gression [20, 32–37]. We have used a 3D in vitro system
for the study over time (4D) of breast cancer in the con-
text of its microenvironment termed the mammary archi-
tecture and microenvironment engineering (MAME) model
[30]. Coculture of various cell types in these pathomimetic
avatars allows for recapitulation of in vivo architecture of
breast cancer tissue and serves as a tractable platform to
study and image cell-cell and cell-matrix interactions in
real time (4D).
In the present study, we used both MAME and
xenograft (orthotopic and subrenal capsule) models to
examine the effects of MEPs and CAFs in regulating the
invasive transition of DCIS cells. Our data demonstrate
that the tumor-promoting effects of CAFs in vivo can be
diminished by the presence of MEPs. Using MAME
models, we further show that MEPs reduce the dysplastic
phenotype of DCIS cells and inhibit CAF-induced ECM
proteolysis and invasion by DCIS structures in vitro. Our
MAME data also suggest that MEPs suppress the invasive
transition of DCIS via increased plasminogen activator
inhibitor 1 (PAI-1) secretion. Moreover, the effects of
MEPs can supersede tumor-promoting CAFs by blocking
IL-6 signaling pathways.
Methods
Materials
Reconstituted basement membrane (rBM; Cultrex re-
duced growth factor) was purchased from Trevigen
(Gaithersburg, MD, USA). Dye-quenched collagen IV
(DQ-collagen IV), DQ-collagen I, Alexa Fluor 546 phal-
loidin, Hoechst 33342, SlowFade reagent, polyclonal
anti-p63 antibody, polyclonal cytokeratin 14 (CK14) anti-
body, fluorescein isothiocyanate-conjugated, affinity-
purified donkey antimouse immunoglobulin G (IgG) and
normal donkey serum, normal goat serum, the LIVE/
DEAD® Viability/Cytotoxicity Kit, and SYBR® Green I were
purchased from Thermo Fisher Scientific (Waltham, MA,
USA). Lenti-RFP (red fluorescent protein [RFP]) and lenti-
YFP (yellow fluorescent protein [YFP]) were purchased
from Lentigen (Gaithersburg, MD, USA). PAI-1 protein
was obtained from EMD Chemicals (Gibbstown, NJ, USA).
Antihuman laminin-5 γ2-chain, domain III (EMD Milli-
pore, Billerica, MA, USA) recognizes laminin-332 (lam-
inin-5 in previous nomenclature) and its isoforms laminin-
3A32 (laminin-5A) and laminin-3B32 (laminin-5B). Re-
combinant plasminogen activator inhibitor 1 (rPAI-1) pro-
tein, mutated to increase its stability, was purchased from
EMD Millipore (Billerica, MA, USA). Polyclonal anti-uPA
and polyclonal anti-urokinase plasminogen activator recep-
tor (anti-uPAR) antibodies were kind gifts from Dr. Gunilla
Hoyer-Hanson (Finsen Centre, Copenhagen, Denmark).
Monoclonal antibodies to uPAR (ATN-617) were kindly
provided by Dr. Andrew Mazar (Northwestern University,
Evanston, IL, USA). Human cytokine antibody arrays
(AAH-CYT-G5) were obtained from RayBiotech (Nor-
cross, GA, USA). Human affinity-purified IL-6 neutralizing
antibody (nAb; AF-206-NA) was purchased from R&D
Systems (Minneapolis, MN, USA), and anti-glyceraldehyde
3-phosphate dehydrogenase (anti-GAPDH) was obtained
from EMD Millipore (Billerica, MA, USA). Monoclonal
anti-CD10 antibody was purchased from Abcam
(Cambridge, MA, USA). Acrylamide, nitrocellulose mem-
branes, and protein assay reagents were obtained from
Bio-Rad Laboratories (Hercules, CA, USA). Prestained
protein markers and chemiluminescence immunoblotting
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detection kits were purchased from PerkinElmer (Boston,
MA, USA). HRP-labeled goat antirabbit and goat anti-
mouse IgG were obtained from Pierce Biotechnology
(Rockford, IL, USA). Mammary epithelial basal medium
(MEBM) without phenol red and mammary epithelial
growth medium (MEGM) SingleQuots were purchased
from Lonza (Basel, Switzerland). HyClone FBS was ob-
tained from GE Healthcare Life Sciences (Logan, UT,
USA). CB17/Icr/Hsdscid severe combined immunodefi-
ciency (SCID) mice were purchased from Harlan Labora-
tories (Indianapolis, IN, USA). Masson’s Trichrome Stain
Kit, biotinylated streptavidin-HRP secondary antibody, and
3,3′-diaminobenzidine tetrahydrochloride were obtained
from Dako (Carpinteria, CA, USA). Human breast tissue
microarray (BR8011) from US Biomax (Rockville, MD,
USA). ImmPRESS™ antimouse IgG, normal horse serum,
ImmPACT™ NovaRED™ substrate, avidin-biotin complex-
HRP complex, and VectaMount mounting medium were
obtained from Vector Laboratories (Burlingame, CA,
USA). Sequencing grade modified trypsin was purchased
from Promega (Madison, WI, USA). The Dionex μ-
precolumn C18 reversed-phase cartridge and Acclain Pep-
Map100 C18 reversed-phase analytical column were pur-
chased from Thermo Fisher Scientific (Sunnyvale, CA,
USA). High-performance liquid chromatography (HPLC)
grade water and acetonitrile (Optima) were purchased
from Fisher Scientific (Pittsburgh, PA, USA). Bradford
protein assay kits were obtained from Thermo Fisher
Scientific. Bovine serum albumin, antibiotics, monoclonal
anti-α-smooth muscle actin (anti-αSMA), Triton X-100,
protease inhibitor cocktail, and all other chemicals, unless
otherwise stated, were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Antihuman CK17 antibody, clone
E3, was purchased from Dako.
Cells and cell culture
MCF-10A human breast cell variants [38] and WS-12T
human breast fibroblasts [39] were originally established
at and obtained from the Michigan Cancer Foundation
(the institutional precursor to the Barbara Ann Karmanos
Cancer Institute, Detroit, MI, USA). SUM102 human
breast DCIS cells [40] and N1ME human breast MEPs
were kind gifts of Dr. S. Ethier (Medical University of
South Carolina, Charleston, SC, USA) and Dr. K. Polyak
(Dana-Farber Cancer Institute, Boston, MA, USA), re-
spectively. MCF-10A human breast epithelial cells were
maintained in DMEM/F-12 supplemented with 5% horse
serum, 100 μg/ml insulin, and 5 ng/ml epidermal growth
factor [41]. MCF10.DCIS and SUM102 human breast
DCIS cells were maintained in DMEM/F-12 supple-
mented with 5% horse serum and in Ham’s F-12 media
supplemented with 10% FBS, respectively [20]. N1ME
MEPs, transduced with murine stem cell virus-puro-
human telomerase reverse transcriptase and selected
under 0.4 μg/ml puromycin, were maintained at low pas-
sage in MEGM without phenol red [19]. WS-12T CAFs
were maintained in DMEM-F-12 with 10% FBS [42]. For
3D MAME cultures, MEBM-phenol red free supple-
mented with MEGM was used. MCF10.DCIS and
SUM102 were transduced with lenti-RFP, and WS-12T
was transduced with lenti-YFP, to distinguish cell types in
3D cocultures. Cell lines were authenticated using the STR
PowerPlex 16 System (Promega) and routinely screened for
mycoplasma by microscopy (MycoFluor; Thermo Fisher
Scientific) and reverse transcription-polymerase chain reac-
tion (LookOut; Sigma-Aldrich). Further characterization of
N1ME cells was performed by immunostaining and im-
munoblotting for basal markers αSMA, p63, CK14, CK17,
and CD10 (Additional file 1: Figure S1).
Tissue recombinant xenografts
In vivo experiments were performed with the approval
of the relevant institutional animal care and use commit-
tee. All procedures were reviewed and approved and con-
form to all local, state, and U.S. federal regulatory
standards. CB17/Icr/Hsdscid mice were used for xenograft
studies. MCF10.DCIS (2.0 × 105), N1ME (1.0 × 105), and
WS-12T (4 × 104) alone or in combination were mixed in
type I collagen, and, after overnight incubation at 37 °C,
they were grafted either under the renal capsule or ortho-
topically within the fourth inguinal mammary gland of
eight intact female SCID mice [43, 44]. The use of two
graft sites allows an internal assessment of consistency of
outcomes. The renal capsule site was chosen because of
its high level of vascularity and associated graft take rate,
whereas the orthotopic site has greater biological rele-
vance. Internally consistent observations at both sites
strengthen confidence in the data generated. Surviving
host mice (n = 6–8) were killed after 8 weeks. The kidneys
were removed, and grafts were cut into halves and photo-
graphed before being processed for histology (hematoxylin
and eosin stain, Masson’s trichrome stain for collagen, and
laminin-332) and immunofluorescence (αSMA, p63, and
CK14). Tumors in the mammary gland were processed in
the same manner as the kidney grafts. Graft dimensions
were measured, and the tumor volume was calculated
using the formula volume = width × length × depth × π/6.
Preparation and imaging of live 3D MAME cultures
A seeding ratio of 5:2.5:1 of DCIS cells, MEPs, and
CAFs, respectively, was used for 3D MAME cultures.
Briefly, cells were seeded onto glass coverslips coated
with 50 μl of rBM, overlaid with 2% rBM, and grown for
periods ranging from 4 to 21 days. Optical sections
through the entire depth of the 3D structures were
acquired using a Zeiss LSM 510 Meta nonlinear op-
tical (NLO) confocal microscope (Carl Zeiss Micros-
copy, Thornwood, NY, USA) with a water immersion
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objective and reconstructed in 3D using Volocity soft-
ware (PerkinElmer). Volumes of 3D MAME structures
were quantified using Volocity software. Where indi-
cated, 3D MAME cultures were modified as follows:
(1) CAFs were embedded in a layer of collagen I con-
taining DQ-collagen I directly underneath the rBM
layer, or (2) CAFs were embedded within the rBM
layer containing DQ-collagen IV [30].
Immunostaining of 3D MAME cultures
Cells were grown in 3D on rBM-coated coverslips,
permeabilized, and stained for human laminin-332 and
actin according to our previously published procedures
[41]. Antibodies against human laminin-332, not mouse,
were used to determine expression of the human protein
from cells grown in rBM of mouse origin. Cells were in-
cubated with mouse antihuman laminin-332 (20 μg/ml)
or preimmune mouse IgG (110 μg/ml) overnight at 4 °C.
After being washed with PBS, the cells were incubated
with a 1:1000 dilution of Alexa Fluor-conjugated, affinity-
purified donkey antimouse IgG containing 5% normal
donkey serum and phalloidin (1:50; actin staining) for 1 h.
Live-cell proteolysis assay
3D MAME cultures were prepared and imaged as de-
scribed above with the addition of 25 μg/ml DQ-collagen
IV to the 50 μl of rBM [30]. Prior to imaging, nuclei were
stained with Hoechst 33342. Optical sections in 16 con-
tiguous fields through the entire depth of the 3D structures
were acquired on a Zeiss LSM 510 Meta NLO confocal
microscope using a water immersion objective. 3D recon-
structions of optical sections of each structure were gener-
ated using Volocity software. Fluorescent intensities of
degraded dye-quenched collagen IV fragments (dDQ-IV,
green) are from the entire structure; that is, they are the
sum of intensities in individual optical sections quantified.
Data are represented as total intensity of dDQ-IV/cell
(based on number of nuclei), as total volume of dDQ-IV
(μm3), or as total volume of dDQ-IV (μm3 × 103)/cell.
Treatment of 3D MAME cultures with conditioned media
Conditioned media were collected from MEPs grown in
2D monolayer cultures for 3 days and centrifuged at
150 × g to remove cell debris. MCF10.DCIS and SUM102
cells were then grown in 3D MAME cultures with the
addition of 25 μg/ml DQ-collagen IV (as described above)
for 16 days in the presence and absence of MEP-
conditioned media mixed at a ratio of 1:2 with fresh
MEGM. Conditioned media were added to 3D MAME
cultures prior to the addition of a 2% rBM overlay and re-
placed every other day. On days 8 and 16, live-cell imaging
and quantification of 3D MAME volume were performed
as described above.
Immunoblots of 3D MAME cultures
3D cultures of MEPs, 3D cultures of MCF10.DCIS, and
3D cocultures of DCIS-MEP were grown in 60-mm dishes
for 8 days as described above. Conditioned media were
collected at day 8, centrifuged at 150 × g to remove cell
debris, and concentrated through Ultrafree 100 K and
then 3 K concentrators (EMD Millipore). Cell lysates were
prepared according to our previously published proce-
dures [20]. Cell lysates and conditioned media were loaded
on the basis of DNA concentrations of the cell lysates
[45]. Samples were separated by SDS-PAGE; transferred
onto nitrocellulose membranes; and immunoblotted for
uPA, PAI-1, and GAPDH (loading control) [46].
Treatment of 3D MAME cultures with rPAI-1 and ATN-617
Live-cell proteolysis assays were performed on MCF10.DCIS
or MCF10.DCIS-lenti-RFP cells grown in 3D MAME
cultures in the absence (control) or presence of rPAI-1
(250 nM), preimmune IgG (10 μg/ml), or the uPAR-
blocking monoclonal antibody ATN-617 (10 μg/ml), all
added at the time of seeding [47]. Culture medium was re-
placed every other day with fresh medium containing 2%
rBM and either rPAI-1, preimmune IgG, or ATN-617.
Live-cell imaging and quantification of 3D MAME volume
and DQ degradation were performed as described above.
Treatment of 3D MAME cultures with IL-6 nAb
MCF10.DCIS lenti-RFP or SUM102 cells were grown
with CAFs in 3D MAME cultures as described above in
the presence of 100 ng/ml IL-6 nAb [21]. Negative con-
trols were run with an equivalent concentration of iso-
type control. Culture medium was replaced every other
day with fresh medium containing 2% rBM and 100 ng/
ml IL-6 nAb or an equivalent concentration of isotype
control and then imaged on days 2, 4, 6, and 8. Optical
sections through the entire depth of the 3D structures
were acquired on a Zeiss LSM 510 Meta NLO confocal
microscope using a water immersion objective. Volocity
software was used to generate 3D reconstructions and
quantify the volume of 3D MAME structures.
Tissue microarray
A tissue microarray that included samples of human
breast DCIS and adjacent normal breast (BR8011; US
Biomax) was stained for uPAR and laminin-332. The
microarray was deparaffinized; hydrated; and then
incubated with 7 μg/ml ATN-617 or 10 μg/ml laminin-332
antibodies overnight at 4 °C, washed for 5 minutes, and in-
cubated with ImmPRESS reagent for 30 minutes before be-
ing washed with PBS. The tissue microarray was incubated
with ImmPACT™ NovaRED substrate for 10 minutes,
washed, counterstained with hematoxylin, and mounted in
nonaqueous mounting medium (VectaMount).
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Proteomic analyses
2D and 3D cultures of MEPs, 3D cultures of MCF10.DCIS,
and 3D cocultures of DCIS-MEP were grown in 60-mm
dishes for 8 days. Conditioned media were collected at day
8, centrifuged at 150 × g to remove cell debris, and concen-
trated through Ultrafree 100 K and then 3 K concentrators.
The same volume of growth media from uncoated and
rBM-coated 60-mm dishes was also concentrated and
used as a control. Protein concentration of conditioned
media from 2D and 3D cultures of MEPs, 3D cultures of
MCF10.DCIS, and 3D cocultures of DCIS-MEP and
control media was measured using Bradford reagent ac-
cording to the manufacturer’s procedure. Sample proteins
were precipitated with cold acetone. The washed pellets
were then resuspended in 50 mM trimethylammo-
nium bicarbonate, reduced, alkylated, and digested
with sequencing-grade trypsin (at an estimated 1:20
wt/wt ratio) as previously described [48]. The resulting
peptides were analyzed by nanoscale liquid chromatog-
raphy coupled to tandem mass spectrometry. Peptides
were separated on a reversed-phase C18 column using the
Dionex Ultimate™ HPLC system and a QSTAR XL mass
analyzer (Applied Biosystems, Foster City, CA, USA) as de-
scribed elsewhere [48]. Mass spectrometry was performed
from m/z 400 to 1500 for 1 second, followed by product
ion scanning on the two most intense multiply charged
ions. The peak lists were submitted to the Mascot server
(Matrix Science, Boston, MA, USA) to search against the
UniProt database for Homo sapiens with carbamidomethyl
as a fixed modification and oxidation and N-acetylation
(protein amino-terminus) as variable modifications, 0 or
1 missed tryptic cleavage, 100-ppm mass tolerance for
precursor ions, and 0.6 Da for the fragment ions.
Cytokine antibody array
DCIS cells, MEPs, and CAFs were grown either alone or
in combination in 3D MAME cultures on 60-mm dishes
for 8 days. Media from days 4 and 8 were pooled, centri-
fuged at 150 × g to remove cell debris, and analyzed for
cytokine secretion using antibody arrays as specified by
the manufacturer. Growth media not conditioned by
MAME cultures were used as a negative control.
Statistics
Statistical analyses were carried out using Prism version
7.0 software (GraphPad Software, La Jolla, CA, USA).
One-way analysis of variance (ANOVA) and two-way
ANOVA were used, where specified, to compare means
between the groups, followed by Bonferroni post hoc
analysis to correct for multiple comparisons. Other
statistical analyses were done by two-sided Student’s t
test. For all studies, p ≤ 0.05 was considered statisti-
cally significant.
A sample size of three mice per group was used. Each
mouse contributed to more than one observation, namely
two sites, which provided enough power (approximately
80%) to determine differences between groups. The
statistical method used was ANOVA. Animal experi-
ments were not randomized, but were blinded to the
principal investigator.
Results
MEPs reduce the volume and malignant phenotype of
DCIS xenografts in vivo in two preclinical mouse models:
mammary fat pad and renal capsule
We investigated the suppressive role of MEPs on DCIS
in the absence and presence of tumor-promoting CAFs
using two complementary human tumor xenograft
models. DCIS cells, MEPs, and CAFs were grafted in
various combinations in intact female SCID mice: (1)
orthotopically within the fourth inguinal mammary
gland or (2) under the renal capsule. Tissue recombin-
ation and grafting are well-established approaches to ex-
plore both development and disease and have been used
to study a range of organs, including the mammary
gland [43, 49]. Grafting can be performed either orthoto-
pically, providing the most relevant context, or at the
subrenal capsule site, providing better vascularization
and take rate. Our findings were consistent between
graft sites, although grafts in the highly vascularized
renal capsule tended to be larger, likely reflecting a
higher initial take rate for cells. Coimplantation of nor-
mal MEPs with DCIS cells resulted in orthotopic (Fig. 1a,
top row, and b) and renal capsule xenografts (Fig. 1c, top
row, and d) that were significantly smaller in size than
xenografts of DCIS cells alone. Coimplantation of DCIS
cells with CAFs significantly increased volumes of ortho-
topic xenografts (Fig. 1a, top row) (p < 0.001); however,
changes in histology, such as tissue disorganization, that
are consistent with a more malignant phenotype were
observed in both orthotopic and renal capsule xeno-
grafts (Fig. 1a and c, middle rows). To verify the pres-
ence of MEPs in the xenografts, we stained for and show
colocalization of three basal markers (i.e., αSMA, p63,
and CK14) (Additional file 1: Figure S1). To investigate
the effects of MEPs on the malignant phenotype of DCIS
tumors in the presence of CAFs, all three cell types were
coimplanted in both xenograft models. Even in the pres-
ence of CAFs, MEPs significantly reduced the tumor
sizes to levels similar to xenografts of DCIS and MEPs
without CAFs (Fig. 1b and d). MEPs also reduced colla-
gen deposition in the stroma of DCIS xenografts (Fig. 1a
and c, bottom rows). Because fibroblasts are involved in
collagen deposition during the remodeling of the ECM
in breast cancer progression and invasion [50], these
data further demonstrate the overriding effects of MEPs
on CAFs to suppress the malignant progression of DCIS.
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MEPs reduce the size and dysplastic phenotype of DCIS
structures grown in 3D MAME cultures
Structural integrity and function of the mammary gland
are dependent on interactions between the breast epithe-
lium, basement membrane, and surrounding ECM [3].
MAME 3D pathomimetic models are designed to mimic
the in vivo architecture of breast tissue under controlled
in vitro conditions [30]. We employed MAME cultures
to identify changes in the morphology of breast epithe-
lial cells in the presence and absence of MEPs. One of
the markers we examined was laminin-332 (laminin-5 in
previous nomenclature), which plays crucial roles in cell
adhesion, migration, and differentiation [51]. Although
other laminins are found in the basement membrane,
laminin-332 is of interest because it is expressed in the
invading cells of various malignancies, including breast
ductal carcinomas and their associated MEPs, and is
coexpressed with uPAR in colorectal cancer cells [52].
Furthermore, downregulation of laminin-332 in bladder
carcinoma cells increases the number of invadopodia
and ECM degradation, suggesting a role for laminin-332
in negatively regulating proteolysis and cell invasion
[53]. We also show the presence of laminin-332 in our
DCIS xenografts, with increased staining observed in the
presence of MEPs (Additional file 1: Figure S1). In 6-day
MAME cocultures of nontransformed breast epithelial
cells (MCF-10A) and MEPs, well-organized acinar struc-
tures enclosing a central lumen were observed, with
laminin-332 localized around the acinar structures at the
epithelial-stromal interface (Fig. 2a and b, top row, left
column). These observations can be more clearly visual-
ized in videos of the 3D structures (Additional file 2: Video
a
c
b
d
Fig. 1 Myoepithelial cells (MEPs) reduce volume and malignant phenotype of ductal carcinoma in situ (DCIS) xenografts. MCF10.DCIS (DCIS) cells,
N1ME cells (MEPs), and/or WS-12T (cancer-associated fibroblasts [CAFs]) were implanted under the renal capsule or orthotopically within the
mammary fat pad of female severe combined immunodeficiency mice and evaluated after 8 weeks. a Representative orthotopic xenografts. Scale
bar = 5 mm (top row); hematoxylin and eosin (H&E) staining; scale bar = 100 μm (middle row); and Masson’s trichrome staining for collagen (blue);
scale bar = 100 μm (bottom row). b Volume of orthotopic xenografts (n = 3–8). c Representative renal xenografts. Scale bar = 5 mm (top row); H&E
staining; scale bar = 100 μm (middle row); and Masson’s trichrome staining for collagen (blue); scale bar = 100 μm (bottom row). d Volume of renal
xenografts (n = 6, except for CAFs alone, which were n = 2 and not used in statistical analyses). Data are presented as box-and-whisker plots where the
box represents the interquartile range and whiskers represent minimum and maximum values. * p≤ 0.05; **** p≤ 0.0001 as determined by one-way
analysis of variance and Bonferroni’s multiple comparisons test. Immunostaining and immunoblotting results for basal markers are shown
in Additional file 1: Figure S1
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S1). The MCF-10A acinar structures are similar to those
grown in 3D in the absence of MEPs (Fig. 2b, top row, left
column inset) [30, 41]. By day 21, tubelike structures were
observed linking the 3D acinar structures (Fig. 2a and b,
bottom row, left column), resembling the architecture of
normal breast tissue. The tubular morphology can be seen
more clearly when the 3D reconstructions are rotated
(Additional file 3: Video S2). By comparison, the acinar
structures formed in 6- and 21-day MAME cultures of
DCIS cells alone were larger, lacked lumens, and were less
a
b
Fig. 2 Myoepithelial cells (MEPs) in mammary architecture and microenvironment engineering (MAME) cocultures facilitate organization of MCF-10A
acinar structures and reduce size and dysplastic phenotype of ductal carcinoma in situ (DCIS) structures. Nontransformed breast epithelial cells
(MCF-10A) and MCF10.DCIS cells (DCIS) were grown in MAME cultures in the absence and presence of N1ME cells (MEPs) and imaged live at 6 and
21 days. Red and green represent phalloidin staining of the actin cytoskeleton and immunostaining for human laminin-332, respectively. a 3D
reconstructions of Z-stack images captured at 6 (top rows) and 21 (bottom rows) days in MAME culture and generated with Volocity software. One
grid unit = 23 μm. Inset in top row, left column, is a representative en face view of MCF-10A plus MEPs. b Confocal slices at the equatorial plane of the
structures captured at 6 (top rows) and 21 (bottom rows) days in MAME cultures. Scale bar = 50 μm. Inset in top row, left column, is a representative
image of MCF-10A cells grown alone in MAME culture at day 6. Images are representative of at least three independent experiments. Acinar lumens
(white arrows) and tubular morphology (white bracket) are indicated. Immunostaining for laminin-332 and videos of MCF-10A 3D acinar structures are
shown in Additional file 1: Figure S1, Additional file 2: Video S1, Additional file 3: Video S2, and Additional file 4: Figure S2
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organized (as shown by actin staining), resembling a dys-
plastic phenotype (Fig. 2a and b, middle column). Although
human DCIS cells form 3D structures that are functional
in that they produce and secrete human laminin when
grown in murine rBM, the pattern of laminin-332 staining
was diffuse and localized within, rather than at the edge of,
the acinar structures. Diffuse staining for laminin-332 in
DCIS was also observed in a tissue microarray (Additional
file 4: Figure S2). In the presence of MEPs, 3D DCIS struc-
tures were smaller and more organized, even in some cases
having a lumen (Fig. 2a and b, right column). Moreover,
the diffuse staining of laminin-332 was reduced and local-
ized at the periphery of the acinar structures. These data
suggest that MEPs play a role in the organization of DCIS
cells and in reverting their dysplastic phenotype.
MEPs reduce invasiveness of DCIS structures grown in
MAME cultures
In normal breast tissue, MEPs contribute to the struc-
tural organization of the breast tissue and prevent epi-
thelial cells from migrating and invading into the ECM
[10]. We investigated whether MEPs could reverse the
invasive phenotype of DCIS cells over a 16-day period of
growth in MAME cultures. Owing to the large size of
the DCIS structures, we captured differential interfer-
ence contrast (DIC) images at low magnification from
16 contiguous fields of view and assembled them into a
montage (Fig. 3a, left columns, and b). By using mon-
tages, we can concomitantly compare multiple DCIS
structures. DCIS cells cultured alone formed irregularly
shaped 3D structures and exhibited extensive invasive
outgrowths (Fig. 3a, top row). At higher magnification,
outgrowths could be seen to be comprised of a sheet of
cells that protruded from DCIS structures into the sur-
rounding ECM (Fig. 3a, outlined area and arrow in the
top row, middle column). In 3D reconstructed images,
invasive outgrowths projecting from DCIS structures
into the ECM resulted in the surface of DCIS structures
appearing irregular (Fig. 3a, top row, right column; arrow
in top row, right column, corresponds to arrow in top
row, middle column). These projecting 3D multicellular
outgrowths (arrows) are further illustrated in images
of 3D reconstructions shown from various angles
(Additional file 5: Figure S3). In the presence of MEPs,
DCIS structures had fewer invasive outgrowths (Fig. 3a,
bottom row), as is more apparent at a higher magnification
(Fig. 3a, bottom row, middle column). In 3D reconstructed
images (Fig. 3a, bottom row, right column), the cohesive-
ness of the structures is evident by the smooth surface
(Fig. 3a, bottom row, right column, and Additional file 5:
Figure S3). In DIC images, unstained MEPs were seen sur-
rounding the DCIS cells in the cocultures (Fig. 3a, inset in
bottom row, middle column), consistent with MEPs at-
tenuating the invasive potential of the DCIS cells. In the
presence of tumor-promoting CAFs (ratio of DCIS cells to
CAFs was 5:1), there were numerous invasive outgrowths
formed between DCIS structures (Fig. 3b, top row, red
arrowhead); these CAF-induced outgrowths were sup-
pressed in the presence of MEPs (Fig. 3b, bottom row).
MEPs reduce ECM proteolysis by DCIS structures grown in
MAME cultures
We and other investigators have shown that incorporation
of fibroblasts into 3D rBM cultures can recapitulate effects
of the tumor microenvironment on malignant progression
of DCIS, including enhancing ECM proteolysis [20, 54]. In
the present study, we examined whether MEPs would re-
duce ECM proteolysis by DCIS structures formed in
MAME cultures in the absence and presence of CAFs.
Some variation could be observed as early as 8 days in
culture in the size of DCIS structures and their degree of
DQ-collagen IV degradation when grown alone versus in
combination with CAFs and MEPs (Additional file 6:
Figure S4). Differences were more evident after 21 days
(Fig. 4 and Additional file 6: Figure S4). DCIS cells grown
alone formed large dysplastic structures that degraded
DQ-collagen IV (green) and invaded into the surrounding
matrix (Fig. 4a, top row). Addition of MEPs suppressed
the invasive phenotype of DCIS structures and reduced
degradation of DQ-collagen IV (Fig. 4a and Additional file
6: Figure S4, second rows). Conversely, addition of CAFs
enhanced the dysplastic and invasive phenotypes and the
size of DCIS structures (Fig. 4a and Additional file 6:
Figure S4, third rows). Moreover, in MAME triple cocul-
tures of DCIS, MEPs, and CAFs, MEPs maintained partial
suppression of DCIS progression and invasiveness, despite
the presence of the tumor-promoting CAFs (Fig. 4a and
Additional file 6: Figure S4, bottom rows). We quantified
the DQ-collagen IV degradation products in a minimum
of 64 fields for each of the 4 different MAME cultures and
confirmed that the MEPs significantly suppressed DQ-
collagen IV proteolysis (i.e., volume of degradation
products per cell) by DCIS in the absence and presence of
CAFs (Fig. 4b). We also examined a modified layered
MAME in which CAFs were embedded in a layer of
collagen I plus DQ-collagen I directly underneath the
rBM layer seeded with DCIS cells. The modified MAME
model reflects the location of fibroblasts prior to their in-
filtration into the tumor and allows for the examination of
cell migration and invasion through the ECM. The
distance between DCIS cells and CAFs was reduced after
21 days of coculture, consistent with movement of these
cells toward each other (Fig. 4c). After 21 days of coculture
of DCIS cells, CAFs, and MEPs, the invasive phenotype, in-
cluding degradation of DQ-collagen I and IV, was attenu-
ated (Fig. 4d), further supporting a role for MEPs in
suppressing the tumor-promoting effects of CAFs on
DCIS progression.
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MEP-conditioned media reduce dysplastic phenotype of
DCIS structures and ECM proteolysis
MEPs suppress invasion of tumor cells into the ECM by
the secretion of anti-invasive factors [11, 55]. To deter-
mine whether factors secreted from the MEPs suppress
the dysplastic phenotype of DCIS cells, we treated two
different DCIS cell lines, MCF10.DCIS-lenti-RFP (DCIS)
and SUM102-lenti-RFP (SUM102), with media condi-
tioned by MEPs (MEP-CM). Like MCF10.DCIS cells,
SUM102 cells form large dysplastic structures in 3D
MAME cultures that resemble DCIS lesions seen in vivo
[20] and degrade DQ-collagen IV [20, 30]. At day 16, as
illustrated in the montage of 16 contiguous DIC images
shown in Fig. 5a and b (top rows), MEP-CM reduced the
size of DCIS and SUM102 structures as well as their
invasive outgrowths and DQ-collagen IV degradation
(green; Fig. 5a and b, bottom rows). The decrease in vol-
ume of both DCIS and SUM102 structures in the pres-
ence of MEP-CM is apparent in 3D reconstructed
images captured at days 8 (Additional file 7: Figure S5)
and 21 (Fig. 5c and d). Quantitative analyses confirmed
a significant reduction in the volumes of both DCIS
(Fig. 5e) and SUM102 (Fig. 5f ) structures at day 21. If
CAFs were embedded within the rBM containing DQ-
collagen IV and DCIS cells seeded on top, MEP-CM
was observed to reduce the size of DCIS structures
even in the presence of tumor-promoting CAFs (Additional
file 8: Video S3 and Additional file 9: Video S4).
Again, this is consistent with factors secreted by
MEPs counteracting paracrine signaling between CAFs
a b
Fig. 3 Myoepithelial cells (MEPs) reduce invasive phenotype of ductal carcinoma in situ (DCIS) structures formed in mammary architecture and
microenvironment engineering (MAME) cultures. a MCF10.DCIS-lenti-RFP (DCIS) were seeded in MAME cultures alone or with N1ME cells (MEPs)
and imaged live at day 16. Left columns are tiled images of 16 contiguous differential interference contrast (DIC) fields. Scale bar = 100 μm. Middle
columns are magnified DIC images of the boxed areas in the left columms and illustrate invasive outgrowths from DCIS structures in the absence
of MEPs (outlined area and arrow in top row, middle column). Scale bar = 380 μm. Right columns are 3D reconstructions of Z-stack images of DCIS
structures (red). One grid unit = 90 μm (arrow in top row, right column, corresponds to the same invasive outgrowth highlighted by arrow in top
row, middle column). The inset in the bottom row, middle column, shows an overlay of unlabeled MEPs (DIC) and the absence of outgrowths in
DCIS structures (red) when cocultured with MEPs. Scale bar = 100 μm. b MCF10.DCIS cells (DCIS) and WS-12T cells (cancer-associated fibroblasts
[CAFs]) were seeded with or without N1ME cells (MEPs) in MAME cultures and imaged live at day 8. Arrowhead points to an invasive
outgrowth. Images are 16 contiguous tiled fields (scale bar = 90 μm). Images are representative of at least three independent experiments. Views of
3D reconstructions from a number of angles are shown in Additional file 5: Figure S3
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and DCIS. To verify that this reduction was not due
to an effect on cell viability, we performed a live/dead
assay on DCIS cells treated with MEP-CM for 16 days
and confirmed that the DCIS cells remained viable
(Additional file 10: Figure S6).
rPAI-1 or ATN-617, a uPAR blocking antibody, reduces
proteolysis and growth of DCIS structures
The dramatic reductions in size and invasiveness of
DCIS structures induced by MEP-CM prompted us to
perform proteomic analyses on MEP-CM. In CM of
a c
b
d
Fig. 4 Myoepithelial cells (MEPs) reduce proteolysis of extracellular matrix (ECM) and invasive phenotype of ductal carcinoma in situ (DCIS)
structures formed in mammary architecture and microenvironment engineering (MAME) and modified MAME cultures, respectively. a
Representative angled en face views of 3D reconstructions of structures formed by MCF10.DCIS-lenti-RFP (DCIS, red) cells seeded alone (top row)
or in coculture with N1ME (MEPs, unlabeled; second row), WS-12T-lenti-YFP (cancer-associated fibroblasts [CAFs], pseudocolored fuchsia; third row),
or both CAFs and MEPs (bottom row). The reconstituted basement membrane (rBM) overlay cultures contained dye-quenched collagen IV (DQ-
collagen IV) and were imaged live at 21 days. One grid unit = 92 μm. b Volume of degraded dye-quenched collagen IV (dDQ-IV, green) per cell in
the 4 MAME culture variants was quantified in 64–96 fields (16 contiguous fields per experiment from 4–6 independent experiments) with Volocity
software. Unlabeled cells were used to eliminate possible interference with analysis of fluorescent dDQ-IV degradation products. Degradation products
were quantified per cell number as determined by counting nuclei labeled with Hoechst 33342 in 3D reconstructions assembled from optical sections
through the entire depth of the cultures. Intensities of dDQ-collagen IV fragments in 3D are the sum of intensities in individual optical sections. Using
the nuclei counts, these data were then calculated as volume per cell [(μm3 × 103)/cell]. Data are presented as box-and-whisker plots where
the box represents the interquartile range and whiskers represent minimum and maximum values. * p≤ 0.05; ** p≤ 0.01 as determined by
one-way analysis of variance and Bonferroni’s multiple comparisons test (n = 4–6). Representative angled (c and d, top rows) and en face (c and d,
bottom rows) views of 3D reconstructions of 8- and 21-day MAME cultures with the following culture modifications: WS-12T-lenti-YFP (CAFs,
pseudocolored fuchsia) were embedded in a bottom layer of collagen I containing DQ-collagen I (dDQ-colI, green) and MCF10.DCIS-lenti-RFP (DCIS, red) cells
with (c; 1 grid unit = 92 μm) and without (d; 1 grid unit = 90 μm) MEPs were seeded onto a second layer composed of rBM containing DQ-collagen IV
(dDQ-IV, green). An overlay of 2% rBM was placed on top of the cocultured cells. Images are representative of at least three independent experiments.
Additional results are shown in Additional file 6: Figure S4
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MEPs grown in both 2D and 3D cultures, the highest
protein scores were found for PAI-1, an inhibitor of
plasminogen activation (Additional file 11: Table S1,
Additional file 12: Table S2, and Additional file 13: Table
S3). PAI-1 was also found to have the highest protein
score in CM from DCIS-MEP cocultures, a score that
was also greater than that of DCIS grown alone in 3D
(Additional file 11: Table S1, Additional file 12: Table S2,
and Additional file 13: Table S3). PAI-1 secretion by
these cells was confirmed by immunoblotting (Fig. 6a),
a b
c d
e f
Fig. 5 Myoepithelial cell-conditioned media (MEP-CM) reduce dysplastic phenotype of ductal carcinoma in situ (DCIS) structures formed in
mammary architecture and microenvironment engineering (MAME) cultures. DCIS cells were seeded in reconstituted basement membrane
overlay cultures containing dye-quenched collagen IV (DQ-collagen IV) in the absence (control) or presence of MEP-CM and imaged live at day
16. Differential interference contrast images are 16 contiguous tiled fields of MCF10.DCIS-lenti-RFP (DCIS; a, top rows) and SUM102-lenti-RFP
(SUM102; b, top rows) structures. Scale bars = 180 μm. Fluorescence images are en face views of 3D reconstructions of DCIS (a, bottom rows) and
SUM102 (b, bottom rows) structures (red) and their associated DQ-collagen IV degradation products (green). One grid unit = 45 μm. Representative
angled views of 3D reconstructions illustrating volume of DCIS (c) and SUM102 (d) structures (red). One grid unit = 180 μm. Volumes of
DCIS (e, n = 6) and SUM102 (f, n = 5) structures were quantified in 64 fields (16 contiguous fields per experiment from 4 independent experiments).
Data are presented as box-and-whisker plots where the box represents the interquartile range and whiskers represent minimum and maximum
values. ** p ≤ 0.007; *** p ≤ 0.0005 as determined by unpaired t test, two-sided. Images are representative of at least three independent experiments.
Additional results are shown in Additional file 7: Figure S5, Additional file 8: Video S3, Additional file 9: Video S4, and Additional file 10: Figure S6
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with the highest level of PAI-1 being secreted from
DCIS-MEP cocultures. Among its multiple roles, PAI-1
is an inhibitor of uPA, a secreted serine protease in-
volved in proteolytic cascades that promote tumorigen-
esis [56]. Our immunoblotting data revealed a slight
decrease in secretion of pro-uPA (latent isoform) from
DCIS-MEP cocultures (Fig. 6a). An increase in PAI-1
secretion and a decrease in pro-uPA secretion from
DCIS-MEP cocultures are consistent with the observed
reduction in DQ-collagen IV degradation and invasion
a c e
b
d f
Fig. 6 Analysis and targeting of the plasminogen activation pathway results in decreased extracellular matrix (ECM) degradation by ductal
carcinoma in situ (DCIS) structures formed in mammary architecture and microenvironment engineering (MAME) cultures. a Media conditioned
from 8-day 3D cultures of myoepithelial cells (MEPs) alone, DCIS cells alone, and DCIS-MEP cocultures were analyzed by immunoblotting for
plasminogen activator inhibitor 1 (PAI-1) and pro-urokinase plasminogen activator (pro-uPA). Immunoblotting for glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) in cell lysates was used as a loading control. b Representative images from a tissue microarray containing adjacent normal
and DCIS specimens were stained for human urokinase plasminogen activator receptor (uPAR) with ATN-617 antibody (5 μg/ml) (top rows) and
preimmune immunoglobulin G (IgG) (control). Scale bar = 100 μm (middle rows). In DCIS specimens imaged at a higher magnification, stromal cells
(arrows) can be seen to exhibit strong staining for uPAR. Scale bar = 50 μm (bottom rows). All sections were counterstained with hematoxylin. c
MCF10.DCIS (DCIS) cells were seeded in reconstituted basement membrane (rBM) overlay cultures containing dye-quenched collagen IV (DQ-collagen
IV) in the absence (control) or presence of 250 nM human recombinant plasminogen activator inhibitor 1 (rPAI-1), preimmune IgG (IgG), or 10 μg/ml
uPAR blocking antibody (ATN-617) and imaged live at day 4. Representative angled views of 3D reconstructions of DCIS structures illustrate nuclei
(blue) and DQ-collagen IV degradation products (dDQ-IV, green). One grid unit = 45 μm. d Intensity of dDQ-IV per cell was quantified from a minimum
of three independent experiments using Volocity software (n = 8–14). * p≤ 0.05 and *** p≤ 0.0005 as determined by unpaired t test, two-sided.
MCF10.DCIS-lenti-RFP cells (DCIS, red) were seeded into rBM overlay cultures containing DQ-collagen IV in the absence (control) or presence of rPAI-1
and imaged live at day 4. e Representative angled views of 3D reconstructions of DCIS (red) structures and associated dDQ-IV (green).
One grid unit = 180 μm. f Volumes of DCIS structures (red) and dDQ-IV (green) in the absence (control) and presence of rPAI-1 were quantified
from a minimum of three independent experiments using Volocity software (n = 4). * p≤ 0.05 and ** p ≤ 0.005 as determined by unpaired t test,
two-sided. Data are presented as box-and-whisker plots where the box represents the interquartile range and whiskers represent minimum and
maximum values. Images are representative of at least three independent experiments. Additional results are shown in Additional file 11: Table S1,
Additional file 12: Table S2, and Additional file 13: Table S3
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in these cocultures, as well as with a role for the plas-
minogen pathway, which includes activation of plas-
minogen to plasmin by uPA.
Plasminogen activation and subsequent ECM proteoly-
sis, processes linked to cancer progression and invasion,
involve binding of uPA to its cell surface receptor uPAR
[57]. Inhibition of uPA and its interactions with uPAR
reduces tumor growth and invasion [58, 59]. Having
demonstrated staining for uPAR in DCIS (Fig. 6b, top
row) and associated stromal cells (Fig. 6b, bottom row),
we compared the effects of both rPAI-1 and the uPAR
blocking antibody ATN-617 [47] on degradation of DQ-
collagen IV in MAME DCIS cultures. After 4 days in
culture, degradation of DQ-collagen IV by the DCIS
structures was significantly reduced by either rPAI-1 or
ATN-617 (Fig. 6c and d). To further investigate the ef-
fects of PAI-1, we transduced DCIS cells with lenti-RFP
so that volumes of DCIS structures and associated DQ-
collagen IV degradation products could be measured.
We found that rPAI-1 significantly reduced volumes of
both DCIS structures and DQ-collagen IV degradation
products (Fig. 6e and f). Our results are thus consistent
with PAI-1 secreted by MEPs suppressing DCIS growth,
blocking uPA binding to uPAR, and inactivating proteo-
lytic networks involved in ECM remodeling and invasion.
Blocking IL-6 reduces size of, and ECM degradation by,
DCIS structures
In the breast tumor microenvironment, fibroblasts pro-
mote growth and invasion through cytokine signaling
[21, 60]. To assess if changes in morphology and growth
of DCIS are due to modulation of cytokine secretion by
CAFs, DCIS cells were grown either alone or with CAFs
and/or MEPs for 8 days. The cytokines IL-6, epithelial-
derived neutrophil-activating peptide 78(ENA-78), and
monocyte chemoattractant protein 1 (MCP-1) were
found to be secreted at higher levels from DCIS-CAF
cocultures than from DCIS cultures (Fig. 7a) and at re-
duced levels when MEPs were added to the DCIS-CAF
cocultures (Fig. 7a). Because IL-6 was the cytokine most
abundantly secreted from DCIS-CAF cocultures, we in-
vestigated whether the tumor-suppressing effects of
MEPs on DCIS in the presence of CAFs (i.e., reduced
cell growth, ECM proteolysis, and invasion) were a result
of decreased IL-6 secretion. In the presence of neutraliz-
ing IL-6 antibodies, degradation of DQ-collagen IV was
reduced in DCIS-CAF cocultures (Fig. 7b). Similar results
were observed in MAME cocultures of SUM102 and
CAFs (Additional file 14: Figure S7). To further elucidate
the effect of IL-6 on DCIS growth, the volumes of DCIS-
CAF structures were measured in the presence and ab-
sence of IL-6 neutralizing antibody at days 2, 4, 6, and 8.
As expected, there was a significant reduction in volume
of DCIS-CAF structures (Fig. 7c). Furthermore, blocking
IL-6 reduced invasive outgrowths from the DCIS-CAF
structures (Fig. 7d), effects similar to those observed in
the presence of MEPs (Fig. 3b). Our data are consistent
with an interplay between CAFs and MEPs in which CAF-
secreted IL-6 drives progression and invasion of DCIS via
a mechanism that can be attenuated by MEPs.
Discussion
Premalignant DCIS is considered a nonobligate precur-
sor to invasive carcinoma. Cellular mechanisms that
promote the transition of DCIS to invasive carcinoma
remain unclear [61]. Moreover, the lack of a robust mo-
lecular signature impedes the development of clinical
tests to predict which DCIS lesions will progress to inva-
sive carcinomas [4, 61]. This is further complicated by
the histological and biological diversity of DCIS that
influences the rate of progression, prognosis, and responses
to specific therapies [62]. Studies identifying drivers of
DCIS progression have been focused on stage-specific
changes in the tumor microenvironment [4, 63, 64].
Authors of a recent report identified subtype-specific sig-
natures that underline a role for the tumor microenviron-
ment in predicting the transition of preinvasive to invasive
breast cancer [65]. In the present study, we employed both
mammary and renal xenograft mouse models to assess the
effects of MEPs and CAFs on DCIS progression and a 3D
pathomimetic MAME model of DCIS cultures/cocultures
to study the mechanisms that drive these effects. We reveal
that the tumor-suppressive effects of MEPs on DCIS are
(1) linked to inhibition of uPA/uPAR-mediated proteolysis
by PAI-1 and (2) can reduce the tumor-promoting effects
of CAFs, in part by attenuating the signaling pathways in-
volving the proinflammatory cytokine IL-6.
In normal breast tissue, MEPs are localized between
the luminal epithelial cells and the basement membrane
of the mammary ducts and alveoli. MEPs maintain
proper organization and function of breast tissue by pro-
moting epithelial cell polarity and facilitating expulsion
of glandular secretions while preventing epithelial inva-
sion into the surrounding ECM [10]. The loss of the
MEP layer coincides with a high risk of DCIS progres-
sion into invasive carcinoma [66]. We show in both
mammary and renal xenograft models that, in the pres-
ence of MEPs, DCIS xenografts were smaller, better or-
ganized, and exhibited less collagen deposition than
xenografts of DCIS cells alone. This is consistent with
results obtained in a subcutaneous DCIS xenograft [19].
Our MAME model, which is designed to recapitulate
mammary architecture in vitro [30], also showed a less-
ened dysplastic phenotype of DCIS cells in the presence
of MEPs that was accompanied by reduced DQ-collagen
IV proteolysis, decreased secretion of pro-uPA, and in-
creased secretion of PAI-1.
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Pro-uPA is the secreted precursor of uPA, a serine
protease involved in extracellular proteolytic networks
encompassing many proteases (e.g., plasmin, MMPs, and
cysteine proteases) that promote tumorigenesis, cell
proliferation, invasion, and metastasis [56]. Activation of
pro-uPA involves binding of the latent enzyme to its cell
surface receptor, uPAR. Increased expression of uPA and
uPAR has been linked to poor prognosis of breast cancer
a
b c
d
Fig. 7 Targeting interleukin 6 (IL-6) reduces size and invasiveness of and extracellular matrix (ECM) degradation by ductal carcinoma in situ/
cancer-associated fibroblast (DCIS-CAF) structures formed in mammary architecture and microenvironment engineering (MAME) cocultures. a
Secretion of cytokines was assessed in 8-day conditioned media with a RayBio G5 human cytokine antibody array (RayBiotech, Norcross, GA, USA).
Secretion of IL-6 was significantly elevated (p = 0.002 as determined by one-way analysis of variance [ANOVA]) when MCF10.DCIS (DCIS) cells
were cocultured with WS-12T (CAFs), but it was not reduced when cocultured with myoepithelial cell (MEPs) or with CAFs plus MEPs (arrows).
b MCF10.DCIS-lenti-RFP (DCIS) and WS-12T (CAFs) cells were seeded onto reconstituted basement membrane (rBM) overlaid with 2% rBM in
the presence of isotype control or 100 ng/ml IL-6 neutralizing antibody (nAb) and imaged live at day 8. Representative en face views of 3D
reconstructions of DCIS (red)-CAF (unlabeled) structures and associated degraded dye-quenched collagen IV (dDQ-IV; green) in MAME cultures;
areas of colocalization appear yellow-white. One grid unit = 45 μm. c Volume of structures formed in MAME cultures of DCIS and CAFs in the
presence of isotype control (open circles) or 100 ng/ml IL-6 nAb (filled squares) at days 2, 4, 6, and 8. Volume of structures was measured with
Volocity software (n = 4). Data represent mean ± SD. ** p≤ 0.01 and **** p≤ 0.0001 as determined by two-way ANOVA. d Differential interference
contrast images of MCF10.DCIS (DCIS) and WS-12T (CAFs) MAME cultures in the presence of isotype control or 100 ng/ml IL-6 nAb at day 8.
Images are 36 contiguous tiled fields. Scale bar = 80 μm. Images are representative of at least three independent experiments. Additional results
are shown in Additional file 14: Figure S7. ENA-78 Epithelial-derived neutrophil-activating peptide 78, GRO Growth-related oncogene, MCP Monocyte
chemoattractant protein, GCP-2 Granulocyte chemotactic protein 2, MIF Macrophage migration inhibitory factor, MIP-3 Macrophage inflammatory
protein 3, NAP-2 Neutrophil-activating protein 2
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[56]. In areas of DCIS microinvasion, stromal myofibro-
blasts and macrophages stain for uPA, uPAR, and MMP-
13, suggesting that these proteases work cooperatively in
promoting the transition of DCIS to invasive carcinoma
[67]. Using a 3D collagen I assay, myofibroblasts were
shown to direct breast cancer cell motility in a
plasminogen-dependent manner [68]. We localized
uPAR to both tumor and stromal cells in DCIS tissue and
demonstrated that blocking uPAR in DCIS cells decreased
DQ-collagen IV degradation in vitro. Our data thus sup-
port a role for uPA/uPAR during the transition of DCIS
into invasive carcinoma, a mechanism that may be attenu-
ated by the high levels of PAI-1 secreted by MEPs in pre-
invasive DCIS lesions.
The role of PAI-1 in breast cancer is multifaceted and
stage-specific. Increased PAI-1 alone or in combination
with high uPA levels in breast cancer has been linked to
poor prognosis [69, 70]. Increased PAI-1 expression has
also been observed in MEPs from high-grade DCIS [71,
72]. On one hand, PAI-1 in high-grade DCIS-associated
MEPs may alter cell-matrix adhesion between MEPs and
the underlying basement membrane by disrupting uPAR
binding to basement membrane proteins [73]. Our
studies, on the other hand, suggest a protective role for
PAI-1 secreted by normal MEPs in inhibiting uPA/uPAR
proteolytic pathways involved in ECM degradation.
Hence, a dual role for PAI-1 secreted by MEPs, first as
an inhibitor of uPA, ECM degradation, and tumor
invasion in normal breast and then as a promoter of cell
detachment to facilitate migration and invasion in high-
grade DCIS, would be consistent with the hypothesis
that changes in the tumor microenvironment are major
Fig. 8 A schematic diagram illustrating the use of 3D pathomimetic mammary architecture and microenvironment engineering (MAME) cultures
to identify a divergent interplay between tumor-suppressive myoepithelial cells (MEPs) and tumor-promoting cancer-associated fibroblasts (CAFs)
that involves plasminogen activator inhibitor 1 (PAI-1), urokinase plasminogen activator/urokinase plasminogen activator receptor (uPA/uPAR), and
interleukin 6 (IL-6) and alters the cellular and molecular phenotype of ductal carcinoma in situ (DCIS). ECM Extracellular matrix, rBM Reconstituted
basement membrane
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contributors to DCIS progression. Indeed, changes in
DCIS-associated MEPs have been shown to result in in-
creased expression of proangiogenic and invasive genes
and ECM-degrading proteases (e.g., MMP-2; MMP-14;
and cathepsins F, K, and L) [4, 19, 74]. Moreover, disrup-
tion of signaling pathways that are essential to MEP
differentiation and mediated by transforming growth fac-
tor β, Hedgehog, cell adhesion, and p63 also results in
loss of MEPs and accelerated progression of DCIS to in-
vasive carcinoma [19]. Tumor-associated MEPs are also
deficient in their ability to direct cell polarity of luminal
epithelial cells [75]. These changes in MEPs during
tumorigenesis likely alter the paracrine interactions
between MEPs and stromal cells such as CAFs to facili-
tate tumor invasion.
Numerous studies have shown that CAFs enhance
tumor growth and invasion by secretion of growth fac-
tors, cytokines, and proteases [16, 17]. In the present
study, we show that in the presence of CAFs, orthotopic
and renal capsule DCIS xenografts were larger and ex-
hibited more collagen deposition, a stromal biomarker
of breast cancer progression [76]. In our hands, adding
CAFs to 3D DCIS MAME cultures resulted in larger
structures with more invasive outgrowths and increased
DQ-collagen IV degradation. Previous reports using
both in vivo and in vitro DCIS models showed that
CAFs induce an invasive DCIS phenotype in parallel
with an increase in MMP-14 expression and MMP-9
activity [18, 19]. Interestingly, we show that the tumor-
promoting actions of CAFs on DCIS cells could be at-
tenuated by MEPs both in vivo and in vitro. Further
analysis using our in vitro MAME model revealed that
MEPs significantly decreased IL-6 secretion from DCIS-
CAF cocultures. We previously reported that DCIS pro-
liferation and ECM proteolysis, migration, and invasion
are increased by normal fibroblasts induced to secrete
HGF [20] and CAFs secreting IL-6 [21]. Secretion of
HGF from these normal fibroblasts was correlated with
an increase in uPA and uPAR secretion from DCIS cells
[20]. Moreover, paracrine IL-6 signaling between DCIS
cells and CAFs promotes tumor cell growth and mi-
gration in part through cathepsin B-mediated ECM
degradation [21]. A role for cathepsin B is further
supported by studies showing that suppression of
cystatin A, an endogenous inhibitor of cathepsin B,
increases progression of DCIS to invasive carcinoma
[77]. Previous studies have also shown a tumor-
promoting role for CAFs via IL-6 secretion [23] and an
association between IL-6 secretion and upregulation of
ECM-degrading enzymes (e.g., cathepsin B, MMPs, and
uPA) [21, 24–27]. Our data suggest that MEPs prevent the
tumor-promoting actions of CAFs by blocking secretion
of proinflammatory factors, including IL-6, into the tumor
microenvironment.
Conclusions
Using our 3D pathomimetic MAME cultures, we identi-
fied a divergent interplay between tumor-suppressive
MEPs and tumor-promoting CAFs that involves PAI-1,
uPA/uPAR, and IL-6 and that alters the cellular and mo-
lecular phenotype of DCIS (Fig. 8). We propose that
these interactions evolve during DCIS progression
through changes in the tumor microenvironment that
promote invasion and metastasis. In a 3D compartmen-
talized microfluidic model in which DCIS cells and fi-
broblasts were cocultured separately, factors secreted by
the fibroblasts were shown to change the morphology
and invasiveness of DCIS structures and their remodel-
ing of ECM collagen [32]. Using our MAME models, we
have previously shown that changes in the noncellular
microenvironment also affect the invasive potential of
breast carcinoma cells. For example, MAME cultures of
MDA-MB-231 cells maintained at a slightly acidic pH
(6.8), a pH comparable to that in the microenvironment
of solid tumors, exhibit highly increased degradation of
type IV collagen [34]. We have also used MAME as a
preclinical model to test the effects of cabozantinib on
the tumor-promoting interactions between different
triple-negative breast cancer cells, representing various
molecular subtypes of the disease, and CAFs and normal
fibroblasts overexpressing HGF [78]. One advantage of
using such pathomimetic models to study breast cancer
progression is the control over spatial and physical pa-
rameters of the tumor microenvironment without dis-
turbance of the 3D heterotypic cultures. Another is the
ability to examine differential effects of therapies on
multiple 3D structures that may be consistent with tumor
heterogeneity. These pathomimetic models could also be
adapted for precision medicine using DCIS patient-
derived cells and applied to studies analyzing drug resist-
ance and screening of novel therapeutic approaches.
Additional files
Additional file 1: Figure S1. Characterization of DCIS xenografts and
MEPs using basal markers and laminin-332. MCF10.DCIS (DCIS), N1ME
(MEPs), and/or WS-12T (CAFs) cells were implanted under the renal
capsule or orthotopically within the mammary fat pad of female SCID
mice and evaluated after 8 weeks. Representative (a) orthotopic and (b)
renal xenografts immunostained for αSMA (green, cytoplasmic staining)
and CK14 (red, cytoplasmic staining), p63 (red, nuclear staining), and
Hoechst 33342 (blue nuclei). Arrows represent areas of colocalization.
Original magnification × 60. c Immunoblotting of MEPs shows expression of
αSMA, CD10, and CK17 in N1ME cells. d Representative orthotopic and renal
xenografts immunostained for laminin-332. Scale bar = 100 μm. (PDF 492 kb)
Additional file 2: Video S1. MEPs facilitate organization of acinar
structures by MCF-10A cells in 6-day cocultures. 3D reconstruction of
nontransformed breast epithelial cells (MCF-10A) grown in MAME
cultures in the presence of N1ME cells (MEPs) and imaged live at day 6. Red
and green represent phalloidin staining of the actin cytoskeleton and
immunostaining for human laminin-332, respectively. One grid unit = 23 μm.
(MOV 714 kb)
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Additional file 3: Video S2. MEPs facilitate organization of ductal
structures by MCF-10A cells in 21-day cocultures. 3D reconstruction of
nontransformed breast epithelial cells (MCF-10A) grown in MAME cultures
in the presence of N1ME cells (MEPs) and imaged live at day 21. Red and green
represent phalloidin staining of the actin cytoskeleton and immunostaining
for human laminin-332, respectively. One grid unit = 23 μm. (MOV 22738 kb)
Additional file 4: Figure S2. Laminin-332 staining in normal human
breast and DCIS. Representative images are shown from a tissue microarray
containing adjacent normal and DCIS specimens and stained with human
laminin-332 antibody (10 μg/ml). a Adjacent sections for normal and DCIS
were processed using preimmune IgG (control). Scale bar = 100 μm. b
Higher-magnification images show diffuse staining for laminin-332 in DCIS
cells. Scale bar = 50 μm. All sections were counterstained with hematoxylin.
(PDF 1544 kb)
Additional file 5: Figure S3. MEPs reduce invasive outgrowths from
DCIS structures formed in MAME cultures. MCF10.DCIS-lenti-RFP cells
(DCIS) were seeded into MAME cultures alone or with N1ME cells (MEPs)
and imaged live at day 16. 3D reconstructions of Z-stack images of DCIS
(red) structures (top row) and DCIS (red) plus MEP structures (bottom row)
are shown (green represents DQ-collagen IV degradation products). One grid
unit = 90 μm. Reconstructions are shown in left column in an en face view
and at various angles of view in the other columns. In the top row, the
arrows point to the same invasive outgrowth in each image. (PDF 2002 kb)
Additional file 6: Figure S4. MEPs reduce size of DCIS structures
formed in MAME cultures. Representative angled and en face views of 3D
reconstructions of 8- and 21-day MAME cultures of MCF10.DCIS-lenti-RFP
(DCIS, red) cells seeded alone (top row, grid unit = 92 μm) or in coculture
with N1ME (MEPs, unlabeled; second row, grid unit = 90 μm), WS-12T-
lenti-YFP (CAFs, pseudocolored fuchsia; third row, grid unit = 92 μm), or
both CAFs and MEPs (bottom row, grid unit = 90 μm) in an rBM overlay
culture containing DQ-collagen IV (dDQ-collagen IV, green). Areas of
dDQ-collagen IV on surface of DCIS structures appear yellow. (PDF 654 kb)
Additional file 7: Figure S5. MEP-conditioned media (MEP-CM) reduce
size of DCIS structures formed in MAME cultures. DCIS cells were seeded
in rBM overlay cultures containing DQ-collagen IV in the absence (control)
or presence of MEP-conditioned media (MEP-CM) and imaged live at day 8.
DIC images are 16 contiguous tiled fields of structures formed by two DCIS
cell lines: MCF10.DCIS-lentiRFP (DCIS; a, top rows; scale bars = 90 μm) and
SUM102-lentiRFP (SUM102; b, top rows; scale bars, 180 μm). Fluorescent
images are en face views of 3D reconstructions of DCIS (a, bottom rows)
and SUM102 (b, bottom rows) structures (red) and associated dDQ-IV (green).
One grid unit = 45 μm. (PDF 1373 kb)
Additional file 8: Video S3. CAFs increase dysplastic phenotype of DCIS
structures in 8-day cocultures. 3D reconstructions of 8-day MAME cultures
with the following modifications: MCF10.DCIS-lenti-RFP (DCIS, red) cells
were seeded on rBM containing embedded WS-12T-lenti-YFP (CAFs, pseu-
docolored fuchsia) and DQ-collagen IV (dDQ-IV, green). Merged fluores-
cence appears white. Grid unit = 45 μm. (MOV 10185 kb)
Additional file 9: Video S4. MEP-CM reduce dysplastic phenotype of
DCIS-CAF structures in 8-day cocultures. 3D reconstructions of 8-day
MAME cultures with the following modifications: MCF10.DCIS-lenti-RFP
(DCIS, red) cells were seeded in the presence of MEP-CM on rBM
containing embedded WS-12T-lenti-YFP (CAFs, pseudocolored fuchsia)
and DQ-collagen IV (dDQ-IV, green). Merged fluorescence appears
white. Grid unit = 45 μm. (MOV 12850 kb)
Additional file 10: Figure S6. MEP-conditioned media (MEP-CM) are
not cytotoxic to DCIS structures. MCF10.DCIS (DCIS) cells were seeded
into rBM overlay cultures in the absence (control) or presence of
MEP-conditioned media (MEP-CM). A live/dead assay was performed on
16-day cultures; green and red represent live and dead cells, respectively.
(PDF 119 kb)
Additional file 11: Table S1. Comparative proteomic analysis of
conditioned media from 2D and 3D MEP and DCIS cultures. Protein
scores >28 indicate identity or extensive homology (p ≤ 0.05). ND Not
detected. (PDF 17 kb)
Additional file 12: Table S2. Proteomic analysis of conditioned media
from 2D MEP cultures. (PDF 50 kb)
Additional file 13: Table S3. Proteomic analysis of conditioned media
from 3D MEP and DCIS cultures. (PDF 57 kb)
Additional file 14: Figure S7. Targeting IL-6 reduces size and invasiveness
of and ECM degradation by SUM102-CAF structures formed in MAME cultures.
SUM102-lentiRFP and WS-12T (CAFs) were seeded onto rBM overlaid with 2%
rBM in the presence of isotype control or 100 ng/ml IL-6 neutralizing antibody
(IL-6 nAb) and imaged live at day 8. Representative en face views of 3D
reconstructions of SUM102 (red)-CAF (unlabeled) structures and associated
dDQ-IV (green) in MAME cultures. One grid unit = 45 μm. (PDF 278 kb)
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